mephenytoin

Trade name: mesantoin

Small moleculeapproved

Approved

Oct 23, 1946

Mephenytoin is an antiepileptic drug which can be useful in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Possibly by promoting sodium efflux from neurons, mephenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of posttetanic potentiation at synapses. Loss of posttetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas. Mephenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures. The mechanism of action of mephenytoin is not definitely known, but extensive research strongly suggests that its main mechanism is to block frequency-, use- and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. Mephenytoin is no longer available in the US or the UK. It is still studied largely because of its interesting hydroxylation polymorphism. — NCATS

Clinical trial activity

1 trials · 1 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 1995 (NCT00162383)

Timeline

1940s

  1. Oct 23, 1946

    Sandoz — Earliest FDA Approval

  2. Oct 23, 1946

    Sandoz — NDA Organization

  3. Oct 23, 1946

    Novartis — NDA Secondary Org

Indications

Mechanism of action

Approval history

  • approvedOct 23, 1946

Chemistry & pharmacology

Loading structure…

SMILES

CCC1(NC(=O)N(C)C1=O)C2=CC=CC=C2
Mol. weight
218.2518 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • dl-mephenytoin
  • epiazin
  • fenantoin
  • mephenytoin
  • mephenytoin
  • mephenytoin
  • mephenytoin
  • mephenytoin
  • mephenytoin
  • mephenytoin
  • mephenytoin
  • mephenytoin
  • mephenytoin
  • mephenytoin
  • mersantoin
  • mesantoin
  • mesantoin
  • mesantoin
  • mesdontoin
  • mesontoin
  • methoin
  • methoin
  • methoin
  • methylphenetoin
  • phenantoin
  • phenylethylmethylhydantoin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00162383N/AJul 1, 1995Hebrew University
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hebrew UniversityAcademic/Hospital1111995
1 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
NovartisFor profitNDA2Oct 23, 1946
SandozFor profitNDAOct 23, 1946